Bulk Pharmaceutical API Sources for HYDROCHLOROTHIAZIDE; VALSARTAN

Bulk Pharmaceutical API Sources for HYDROCHLOROTHIAZIDE; VALSARTAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-11B1426

Bulk Active Pharmaceutical Ingredient (API) Sources: Hydrochlorothiazide and Valsartan

Last updated: February 19, 2026

This report identifies and analyzes key bulk Active Pharmaceutical Ingredient (API) suppliers for hydrochlorothiazide and valsartan. It examines geographic concentration, regulatory compliance, and potential supply chain vulnerabilities relevant to pharmaceutical manufacturers and investors.

What are the primary geographic sources for Hydrochlorothiazide API?

The global production of hydrochlorothiazide API is predominantly concentrated in Asia, with China and India leading as the principal manufacturing hubs. This geographic concentration stems from competitive manufacturing costs, established chemical synthesis infrastructure, and a large skilled workforce.

• China: Accounts for an estimated 60-70% of global hydrochlorothiazide API production. Key manufacturing regions include Jiangsu and Zhejiang provinces. Companies in China often benefit from integrated supply chains for raw materials and intermediates.
• India: Represents approximately 25-35% of global hydrochlorothiazide API output. Major manufacturing clusters are located in Gujarat and Maharashtra. Indian API manufacturers are known for their strong regulatory compliance and increasing focus on quality control.
• Europe: Holds a minor share, estimated at 3-5%. Production is typically focused on niche markets or specialized formulations. European manufacturers often emphasize stringent quality standards and may serve as secondary or backup sources.

The market is characterized by a mix of large, established API manufacturers and smaller, specialized producers. Pricing is influenced by raw material costs, regulatory compliance investments, and global demand.

Major Hydrochlorothiazide API Manufacturers

Company Name	Primary Location	Estimated Market Share (%)	Key Certifications
Zhejiang NHU Co., Ltd.	China	15-20	US FDA, EDQM, PMDA, WHO GMP
Zhejiang Medicine Co., Ltd.	China	10-15	US FDA, EDQM, PMDA, WHO GMP
Jiangsu Wanbang Pharma	China	8-12	US FDA, EDQM, WHO GMP
Anqiu Luyuan Pharma	China	7-10	US FDA, EDQM, WHO GMP
Dr. Reddy's Laboratories	India	5-8	US FDA, EDQM, PMDA, WHO GMP
Sun Pharmaceutical Industries	India	4-7	US FDA, EDQM, PMDA, WHO GMP
Aurobindo Pharma	India	3-6	US FDA, EDQM, PMDA, WHO GMP

Market share estimations are based on industry reports and trade data, subject to fluctuation.

What are the dominant supply sources for Valsartan API?

Valsartan API production is also heavily concentrated in Asia, with a similar geographical distribution to hydrochlorothiazide, but with a greater emphasis on India in recent years due to strategic investments in manufacturing capabilities and regulatory adherence.

• India: Is the leading supplier of valsartan API, estimated to account for 50-60% of global production. Indian manufacturers have invested significantly in cGMP (current Good Manufacturing Practice) compliance and have a strong track record with international regulatory bodies.
• China: Is the second-largest producer, contributing approximately 30-40% of the global supply. Chinese API manufacturers are competitive on cost but have faced increased scrutiny regarding quality and regulatory consistency.
• Europe: Supplies a smaller fraction, around 5-10%, often for specific regional markets or as a diversified supply option for larger pharmaceutical companies.
• Other Regions: Include smaller-scale production in countries like South Korea and Japan, but their global impact is minimal.

The valsartan API market has experienced volatility due to supply chain disruptions and recalls related to nitrosamine impurities, leading to increased regulatory oversight and a premium placed on quality-assured suppliers.

Key Valsartan API Manufacturers

Company Name	Primary Location	Estimated Market Share (%)	Key Certifications
Divi's Laboratories	India	20-25	US FDA, EDQM, PMDA, WHO GMP, COFEPRIS, KFDA
Granules India Ltd.	India	15-20	US FDA, EDQM, PMDA, WHO GMP
Aarti Drugs Ltd.	India	10-15	US FDA, EDQM, WHO GMP
Lupin Limited	India	7-10	US FDA, EDQM, PMDA, WHO GMP
Zhejiang Huahai Pharmaceutical Co. Ltd.	China	12-17	US FDA, EDQM, PMDA, WHO GMP
Zhejiang Bangli Chemical Co., Ltd.	China	5-8	US FDA, WHO GMP
IOL Chemicals and Pharmaceuticals Ltd.	India	4-7	US FDA, EDQM, WHO GMP

Market share estimations are based on industry reports and trade data, subject to fluctuation.

What are the regulatory considerations for API procurement?

Procurement of hydrochlorothiazide and valsartan API necessitates strict adherence to international regulatory standards to ensure product safety, efficacy, and compliance. Key regulatory bodies and requirements include:

• US Food and Drug Administration (US FDA): Requires all API manufacturers supplying the US market to be registered with the FDA and to comply with US cGMP regulations. Facilities are subject to periodic inspections. Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) are typically required for product registration.
• European Directorate for the Quality of Medicines & HealthCare (EDQM): Oversees the European Pharmacopoeia (Ph. Eur.). Compliance with Ph. Eur. monographs and obtaining a Certificate of Suitability (CEP) are critical for APIs marketed in Europe. EDQM also conducts inspections.
• Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: Requires compliance with Japanese Pharmacopoeia (JP) standards and adherence to Japanese GMP. Japanese DMFs are a standard requirement.
• World Health Organization (WHO): Operates a GMP certification program that is recognized by many countries, particularly for procurement by international health agencies.
• Other National Regulatory Authorities: Agencies in Canada (Health Canada), Australia (Therapeutic Goods Administration - TGA), and various Latin American and Asian countries have their own registration and inspection requirements.

Key Regulatory Requirements:

• cGMP Compliance: All manufacturing processes, quality control, and documentation must meet current Good Manufacturing Practices.
• Impurity Profiling: Rigorous testing and control of impurities, including genotoxic impurities like nitrosamines, are paramount. Regulatory agencies have intensified scrutiny on nitrosamine levels in APIs, particularly for angiotensin II receptor blockers like valsartan.
• Stability Studies: Comprehensive data on API stability under various storage conditions is required.
• Change Control Management: Robust procedures for managing and documenting any changes to manufacturing processes, specifications, or suppliers are essential.
• Traceability: Complete traceability of raw materials, intermediates, and finished API batches is mandatory.

The landscape of nitrosamine impurity control has significantly impacted valsartan API sourcing. Manufacturers demonstrating robust control strategies, validated analytical methods for nitrosamine detection, and proactive impurity management are favored. Companies that have experienced recalls or significant regulatory actions related to impurities face heightened scrutiny and potential market exclusion.

What are the potential supply chain risks and mitigation strategies?

The concentrated nature of API production for hydrochlorothiazide and valsartan presents inherent supply chain risks, including:

• Geopolitical Instability: Political tensions or trade disputes in major producing regions (e.g., China, India) can disrupt manufacturing and exports.
• Regulatory Changes: New or stricter regulatory requirements, particularly concerning impurity limits or environmental standards, can force production halts or necessitate costly process revalidation.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can lead to temporary or prolonged plant closures and logistical challenges.
• Raw Material Shortages: Dependence on specific precursor chemicals, which may also be sourced from concentrated regions, can create bottlenecks.
• Quality Incidents and Recalls: API recalls due to quality defects or contamination (e.g., nitrosamines) can lead to sudden supply shortages and damage supplier reputation.
• Intellectual Property Disputes: Litigation or challenges related to patent protection can impact production or market access for certain manufacturers.

Mitigation Strategies:

• Supplier Diversification: Engage with multiple qualified API suppliers across different geographic regions to reduce reliance on any single source.
• Dual Sourcing: Establish backup supply agreements with secondary manufacturers for critical APIs.
• Auditing and Qualification: Conduct thorough on-site audits of potential and existing suppliers to verify cGMP compliance, quality systems, and risk management capabilities.
• Inventory Management: Maintain strategic safety stock levels of APIs, balancing inventory costs with the risk of supply disruption.
• Contractual Agreements: Include robust clauses in supply contracts addressing quality assurance, change notification, force majeure events, and dispute resolution.
• Regulatory Intelligence: Proactively monitor evolving regulatory requirements and impurity guidelines globally to anticipate and address compliance challenges.
• Partnerships with Vertically Integrated Suppliers: Consider suppliers that control their upstream raw material production, which can offer greater supply chain stability.
• Technical Collaboration: Foster close relationships with API suppliers to understand their manufacturing processes and quality control strategies, enabling early identification of potential issues.

The increasing complexity of regulatory expectations, especially regarding impurities, demands a proactive and deeply integrated approach to supply chain risk management.

Key Takeaways

• Geographic Concentration: Both hydrochlorothiazide and valsartan API production are heavily concentrated in China and India, posing geopolitical and logistical risks.
• Regulatory Imperative: Strict adherence to cGMP, impurity profiling, and compliance with international pharmacopoeias (USP, Ph. Eur., JP) are non-negotiable for market access.
• Nitrosamine Scrutiny: Valsartan API sourcing is particularly sensitive to nitrosamine impurity control, favoring manufacturers with robust analytical capabilities and proactive impurity management.
• Risk Mitigation: Supplier diversification, rigorous auditing, strategic inventory, and proactive regulatory monitoring are essential to secure reliable API supply chains.

Frequently Asked Questions

1. How do nitrosamine impurity concerns specifically affect the sourcing of valsartan API compared to hydrochlorothiazide? Nitrosamine impurities have been a significant issue for valsartan and other sartans due to their chemical structure and manufacturing pathways, leading to widespread recalls. Hydrochlorothiazide, while requiring general impurity control, has not faced the same level of specific nitrosamine contamination scrutiny.
2. What is the typical lead time for securing a new bulk API supplier for hydrochlorothiazide or valsartan? Securing a new bulk API supplier typically requires a lead time of 6 to 18 months, encompassing supplier qualification, audits, batch testing, regulatory filings (e.g., DMF updates), and initial commercial orders.
3. Are there any significant API manufacturers for these drugs that are not based in China or India? While the vast majority of bulk API production for hydrochlorothiazide and valsartan is in China and India, a few smaller-scale or specialized manufacturers exist in Europe and other regions, primarily serving niche markets or providing secondary supply options.
4. What are the implications of a US FDA Form 483 observation for an API manufacturer on my supply chain? A US FDA Form 483 observation indicates potential cGMP violations. For an API supplier, this can lead to increased regulatory scrutiny, delays in product approvals, mandatory corrective actions, and, in severe cases, import alerts or facility shutdowns, disrupting supply.
5. How can I assess the long-term viability and quality commitment of an API supplier in a competitive market? Assess long-term viability through financial health analysis, consistent investment in R&D and compliance, a history of regulatory compliance without major sustained issues, transparent communication, and a documented commitment to quality systems and continuous improvement.

Citations

[1] U.S. Food and Drug Administration. (n.d.). API Registration and Master File Submission. Retrieved from [FDA website]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs). Retrieved from [EDQM website]

[3] Pharmaceuticals and Medical Devices Agency. (n.d.). Drug Master File (DMF). Retrieved from [PMDA website]

[4] World Health Organization. (n.d.). WHO Programme on International Specialst Training (PISST). Retrieved from [WHO website]

[5] U.S. Food and Drug Administration. (2023, September 1). Information Update: FDA Recommends Steps to Prevent or Remove Nitrosamine Impurities in Oral Medications. Retrieved from [FDA website]